FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130302511> ?p ?o ?g. }

• W3130302511 endingPage "100043" @default.
• W3130302511 startingPage "100043" @default.
• W3130302511 abstract "Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of 'platinum-sensitive' ovarian cancer and has been shown to improve progression-free survival (PFS).ICON6 (NCT00532194) was an international three-arm, double-blind, placebo-controlled randomised trial. Between December 2007 and December 2011, 456 women were randomised, using stratification, to receive either chemotherapy with placebo throughout (arm A, reference); chemotherapy with concurrent cediranib, followed by maintenance placebo (arm B, concurrent); or chemotherapy with concurrent cediranib, followed by maintenance cediranib (arm C, maintenance). Due to an enforced redesign of the trial in September 2011, the primary endpoint became PFS between arms A and C which we have previously published, and the overall survival (OS) was defined as a secondary endpoint, which is reported here.After a median follow-up of 25.6 months, strong evidence of an effect of concurrent plus maintenance cediranib on PFS was observed [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.44-0.72, P < 0.0001]. In this final update of the survival analysis, 90% of patients have died. There was a 7.4-month difference in median survival and an HR of 0.86 (95% CI: 0.67-1.11, P = 0.24) in favour of arm C. There was strong evidence of a departure from the assumption of non-proportionality using the Grambsch-Therneau test (P = 0.0031), making the HR difficult to interpret. Consequently, the restricted mean survival time (RMST) was used and the estimated difference over 6 years by the RMST was 4.8 months (95% CI: -0.09 to 9.74 months).Although a statistically significant difference in time to progression was seen, the enforced curtailment in recruitment meant that the secondary analysis of OS was underpowered. The relative reduction in the risk of death of 14% risk of death was not conventionally statistically significant, but this improvement and the increase in the mean survival time in this analysis suggest that cediranib may have worthwhile activity in the treatment of recurrent ovarian cancer and that further research should be undertaken." @default.
• W3130302511 created "2021-03-01" @default.
• W3130302511 creator A5007606531 @default.
• W3130302511 creator A5011138537 @default.
• W3130302511 creator A5014097745 @default.
• W3130302511 creator A5014804968 @default.
• W3130302511 creator A5021894535 @default.
• W3130302511 creator A5023247842 @default.
• W3130302511 creator A5026047065 @default.
• W3130302511 creator A5027071888 @default.
• W3130302511 creator A5027988619 @default.
• W3130302511 creator A5042726718 @default.
• W3130302511 creator A5047753094 @default.
• W3130302511 creator A5053919588 @default.
• W3130302511 creator A5056374236 @default.
• W3130302511 creator A5072712459 @default.
• W3130302511 creator A5074904071 @default.
• W3130302511 creator A5079383798 @default.
• W3130302511 creator A5081453094 @default.
• W3130302511 date "2021-04-01" @default.
• W3130302511 modified "2023-09-27" @default.
• W3130302511 title "Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial" @default.
• W3130302511 cites W1608269846 @default.
• W3130302511 cites W1793338775 @default.
• W3130302511 cites W1966714873 @default.
• W3130302511 cites W1976301747 @default.
• W3130302511 cites W2026697154 @default.
• W3130302511 cites W2096415778 @default.
• W3130302511 cites W2097373408 @default.
• W3130302511 cites W2104998982 @default.
• W3130302511 cites W2108756633 @default.
• W3130302511 cites W2109240520 @default.
• W3130302511 cites W2113122060 @default.
• W3130302511 cites W2122492414 @default.
• W3130302511 cites W2133537644 @default.
• W3130302511 cites W2135947389 @default.
• W3130302511 cites W2140043667 @default.
• W3130302511 cites W2151050516 @default.
• W3130302511 cites W2151509048 @default.
• W3130302511 cites W2151981428 @default.
• W3130302511 cites W2152376701 @default.
• W3130302511 cites W2154056804 @default.
• W3130302511 cites W2160959204 @default.
• W3130302511 cites W2165630767 @default.
• W3130302511 cites W2166573361 @default.
• W3130302511 cites W2170928115 @default.
• W3130302511 cites W2171658624 @default.
• W3130302511 cites W2200887263 @default.
• W3130302511 cites W2268710619 @default.
• W3130302511 cites W2293618284 @default.
• W3130302511 cites W2593027991 @default.
• W3130302511 cites W2605456582 @default.
• W3130302511 cites W2755816097 @default.
• W3130302511 cites W2914070427 @default.
• W3130302511 cites W2936913298 @default.
• W3130302511 cites W2946425279 @default.
• W3130302511 cites W2951714360 @default.
• W3130302511 cites W2965052442 @default.
• W3130302511 cites W3031903430 @default.
• W3130302511 cites W4210987384 @default.
• W3130302511 doi "https://doi.org/10.1016/j.esmoop.2020.100043" @default.
• W3130302511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7903311" @default.
• W3130302511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33610123" @default.
• W3130302511 hasPublicationYear "2021" @default.
• W3130302511 type Work @default.
• W3130302511 sameAs 3130302511 @default.
• W3130302511 citedByCount "13" @default.
• W3130302511 countsByYear W31303025112021 @default.
• W3130302511 countsByYear W31303025112022 @default.
• W3130302511 countsByYear W31303025112023 @default.
• W3130302511 crossrefType "journal-article" @default.
• W3130302511 hasAuthorship W3130302511A5007606531 @default.
• W3130302511 hasAuthorship W3130302511A5011138537 @default.
• W3130302511 hasAuthorship W3130302511A5014097745 @default.
• W3130302511 hasAuthorship W3130302511A5014804968 @default.
• W3130302511 hasAuthorship W3130302511A5021894535 @default.
• W3130302511 hasAuthorship W3130302511A5023247842 @default.
• W3130302511 hasAuthorship W3130302511A5026047065 @default.
• W3130302511 hasAuthorship W3130302511A5027071888 @default.
• W3130302511 hasAuthorship W3130302511A5027988619 @default.
• W3130302511 hasAuthorship W3130302511A5042726718 @default.
• W3130302511 hasAuthorship W3130302511A5047753094 @default.
• W3130302511 hasAuthorship W3130302511A5053919588 @default.
• W3130302511 hasAuthorship W3130302511A5056374236 @default.
• W3130302511 hasAuthorship W3130302511A5072712459 @default.
• W3130302511 hasAuthorship W3130302511A5074904071 @default.
• W3130302511 hasAuthorship W3130302511A5079383798 @default.
• W3130302511 hasAuthorship W3130302511A5081453094 @default.
• W3130302511 hasBestOaLocation W31303025111 @default.
• W3130302511 hasConcept C121608353 @default.
• W3130302511 hasConcept C126322002 @default.
• W3130302511 hasConcept C141071460 @default.
• W3130302511 hasConcept C142724271 @default.
• W3130302511 hasConcept C143998085 @default.
• W3130302511 hasConcept C168563851 @default.
• W3130302511 hasConcept C203092338 @default.
• W3130302511 hasConcept C204787440 @default.
• W3130302511 hasConcept C207103383 @default.

• next